Coave Therapeutics Showcases Breakthrough in Peptide-Based Conjugated AAV Vectors Using ALIGATER™ Platform in a Late-Breaking Abstract at ESGCT 2024
22 oct. 2024 06h00 HE
|
Coave Therapeutics
Coave’s proprietary ALIGATER platform enables specific retargeting of AAV vectors to human receptors via a one-step chemical conjugation of peptide-based ligands at the surface of the capsid,...
Coave Therapeutics to Present Novel Data Highlighting the Potential of its ALIGATER™ Platform to Enhance the Targeted Delivery of Genetic Medicines at Upcoming Conferences
24 sept. 2024 06h00 HE
|
Coave Therapeutics
Paris, France, September 24, 2024 – Coave Therapeutics (‘Coave’), a genetic medicine company pioneering therapies for eye and neurodegenerative diseases, will present the first data on its...
EyeDNA Therapeutics Announces Positive 24-month Data Presented at ARVO from Ongoing Phase I/II Trial of HORA-PDE6b Gene Therapy in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b
07 mai 2024 03h00 HE
|
Coave Therapeutics
Clinically meaningful benefit in visual functions and good safety profile of HORA-PDE6b is confirmed at 24-month follow-up Phase I/II results will be discussed with US and...
Coave Therapeutics Showcases its ALIGATER™ Platform for Generating Conjugated AAV (coAAV) Vectors Exhibiting Superior Performance in Delivering Ocular Gene Therapy through the Suprachoroidal Route
29 avr. 2024 06h00 HE
|
Coave Therapeutics
coAAV-mediated gene transfer holds promise for expanding the scope of ocular diseases treatable via suprachoroidal administration Data to be presented in oral session at ASGCT 2024 Paris,...
eyeDNA Therapeutics to Present 2-year Follow-up Phase I/II Data on its Investigational Gene Therapy HORA-PDE6b for Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
25 avr. 2024 06h00 HE
|
Coave Therapeutics
Paris, France, April 25, 2024 – eyeDNA Therapeutics (‘eyeDNA’), a newly created subsidiary of Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies,...
Coave Therapeutics to Present at Upcoming Conferences
27 mars 2024 07h00 HE
|
Coave Therapeutics
Paris, France, March 27, 2024 – Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies, announces that its management will be attending the following...
Coave Therapeutics Receives Grant from the ALS Association to Advance its CTx-TFEB Program as a Potential Treatment for All Forms of ALS
29 févr. 2024 07h00 HE
|
Coave Therapeutics
CTx-TFEB is a novel, targeted genetic medicine approach designed to promote autophagy and reduce the accumulation of toxic protein aggregates in neurons Funding aims to support the progression of...
Coave Therapeutics appoints Leading World Experts to newly formed Scientific Advisory Board dedicated to its Genetic Medicine Delivery Platform
12 oct. 2023 07h00 HE
|
Coave Therapeutics
Paris, France, October 12th, 2023– Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies, announces the formation of its new Scientific Advisory Board...
Coave Therapeutics to Present at Upcoming Conferences
28 sept. 2023 08h15 HE
|
Coave Therapeutics
Paris, France, September 28, 2023 – Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies for CNS (Central Nervous System) and eye diseases, announces...
Coave Therapeutics Appoints Genetic Medicine Expert Lolita Petit, PhD as Chief Scientific Officer
21 sept. 2023 06h00 HE
|
Coave Therapeutics
Paris, France, September 21, 2023 – Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies for CNS (Central Nervous System) and eye diseases, announces...